Investor Presentation • Nov 25, 2020
Investor Presentation
Open in ViewerOpens in native device viewer

Financial Statements Investors Presentation



Mr. Eyal Ben Simon, CEO
From the CEO's Desk The company's results in the last quarter demonstrate once again the group's ability to maintain financial strength and stability even during the Covid-19 pandemic. We continued to drive accelerated growth, focusing on activities that generate higher profitability and returns over time. We will continue to improve our product mix, increasing the share of high yieldgenerating assets over activities requiring higher capital allocations.
We continued our focus on building the group's portfolio and synergies between companies. As Excellence Investment House and our asset management and financial activities continued to show exceptional results, we continued our organic growth efforts. Our offer to acquire Hellman-Aldubi is an expression of this strategy.
The onset of Covid-19 has prompted us to work faster to create technological and operational infrastructure, improving our flexibility and dynamism required in this changing reality. We will continue to increase efficiency within the company and invest in technological and digital transformation. As a result of these and other key efforts, the company won first place in overall customer service levels for all major Israeli insurance companies.
This quarter, the Phoenix continued to develop its distribution channels, insurance agencies and direct (Smart and others), while focusing on customer satisfaction across services and activities.
During the quarter, we formulated a dividend distribution policy at a rate that will not be less than 30% of the annual comprehensive profit (this distribution includes the announced share repurchase plan).
We have recently completed the formulation of a multi-year strategic plan for the group's main areas of activity. The plan is formulated with the assistance of an international consulting firm with relevant expertise, accompanying the Strategy Committees of the company and Phoenix Insurance. We will communicate plan highlights during December. This plan forms the foundation for creating the next breakthrough for Phoenix.






| Resilient performance led by continuous improvement of AUM |
AUM | 218 222 as of as of NIS Bn NIS Bn September 30, October 31, 2020 2020 |
|---|---|---|
| Market cap exceeds pre-Covid-19 levels despite the ongoing crisis |
1 Market cap |
5.1 P/B 0.72 NIS Bn |
| Shareholder's Equity, as of 30.09.2020, totaled NIS 7.1 bn, compared to NIS 6.6 bn as of 31.12.2019. |
Shareholders' equity |
7.1 NIS Bn |
| Profits of NIS 323m in Q3/20 and NIS 494m in 1-9/20. Q3/20 profits benefited from market recovery. |
Shareholders' comprehensive income |
1-9/20 494 Q3 323 NIS m NIS m |
| Investmentsloss recovery, leads to variable fee collection expectation as soon as Q4/20 |
2 Covid-19 negative impact |
3 333 176 post balance NIS m NIS m investment recovery |
| New dividend distribution policy - minimum of 30% of comprehensive income |
Solvency | 31.12.2019 4 165% |
| Continuous improvement in ROE during Q3/20, however remain lower than 5Y average |
ROE | 9.7 13.3 1-9/20 5Y % % average |
1) As of November 12, 2020.
2) Post tax, see appendix A.
3) Pro forma investments adjustment, post-tax, related to Nostro marketable assets as of 01.10.2020 – 11.11.2020. please refer to slide 19.
4) The solvency ratio regardless of the transition provisions during the deployment period is at a rate of 105%.


1-9/20 Vs 1-9/19 (NIS m) Q3/20 Vs Q3/19 (NIS m)
Resilient performance led by continuous improvement of Q3 results
COVID-19 Post BS IMPACT NIS 176m 2


1) NON-GAAP Adjustments post tax, for further information please refer to Appendix A.
2) Pro forma investments adjustment, post-tax, related to Nostro marketable assets as of 01.10.2020 – 11.11.2020
NIS (333m)
Results
(Does not include variable management fees). please refer to slide 19.
3) 9M is an abbreviation for 9 months

Significant capital market impact on Q3 results pushes profit higher
• Capital markets and interest influence in 9M/20 totaled NIS 164m, and in Q3 NIS 374m
(*) Investment income above 3% annual return


8
Decrease in premiums and benefit contributions, upward trend post Balance Sheet date
P&C- average premium decrease industry wide impacted overall premiums collected
Health – Mehuhedet HMO leaving heavily impacted the overall premiums collected, with minor impact on profit


AUM exceeded pre-COVID-19 levels and maintained the upward trend post Balance Sheet date





Q3-19 24 (178) 40 (114)
1) NON-GAAP Adjustments pre tax, for further information please refer to Appendix A.
11
64

76
136



COVID-19 IMPACT NIS (5m) 1




Q3-20 5 74 (57) (15) 7
Subsidiaries Investments Q3/20
Other
Q3/19 Financial Expenses
Q3-19 7 172 (27) (9) 143
changes and series 2 to series 5 bond exchange
Results
1) NON-GAAP Adjustments pre tax, for further information please refer to Appendix A.





Appendix A
NON GAP: COVID 19 ECONOMIC IMPACT
COVID-19 Non GAAP impact adjustments: Adjustments of the impact reported at the financial statements to the economic impact of COVID-19.
NIS m Investment (1) Interest (2) Underwriting impcat (3) Total Impact Economic impact (Pre Tax) (4) Total Impact (Pre Tax) Tax Total COVID-19 impact (Post Tax) P&C 47 2 (15) 34 (74) (40) 13 (27) Health 80 (300) 2 (218) (49) (267) 91 (176) LTS 39 98 - 137 (226) (89) 30 (59) Agencies (3) - - (3) - (3) 1 (2) CO (1) - - (1) (103) (104) 35 (69) Total impact 162 (200) (13) (51) (452) (503) 170 (333)
(1) Marketable and non-marketable assets before tax as reported in the Covid-19 Note 1 (section 3) in the financial reports and after offsetting the guaranteed yield to policyholders of approximately NIS 258m in LTS segment.
(2) The Company refers to interest rate changes during 1-9/20 as a Covid-19 impact due to global monitory policy. For further details on the global monitory policy please refer to section 3 of the BOD report. For further details on the relevant adjustments please refer to Note 7 of the financial report. (In Health segment not including the reclassification of asset value surplus that is not related to Covid-19 impact of approximately NIS 121m). More further details regarding interest impacts please refer to section (7)(1) of the financial reports.
Financial Reports (Pre Tax)1
(3) For Covid-19 impact on underwriting results see Note 1 section 2(b) and 2(C). (In Health –NIS 19m is added to the Covid-19 impact due to the decrease in claim frequency)
(4) Investments under assumption of ( 3% + CPI )annual return including non collection of variable management fees of approximately NIS 92m (under assumption of 3%+CPI) in LTS segment under.

COVID-19 Impact
•
Balance Sheet As of 30/09/2020 (ILS m)
| Total assets for yield dependent contracts and | |
|---|---|
• Total assets are up approximately 1,574 compared to 31/12/2019, reflecting overall Balance Sheet stability
| Assets | 30/09/2020 | 31/12/2019 | Liabilites | 30/09/2020 | 31/12/2019 |
|---|---|---|---|---|---|
| Total asssets for yield-dependent contracts in consolidated insurance company |
71,617 | 71,662 | Liabilities in respect of yield dependent insurance contracts and investments contracts |
71,099 | 71,091 |
| Other Financial investments | 26,460 | 24,809 | Liabilities in respect od non yield-dependent insurance contracts and investments contracts |
23,405 | 23,192 |
| Financial investments and cash for holders of debt instruments, ETFs, short ETFs, complex ETFs, currency ETFs, and structured bonds |
252 | 284 | Liabilites in respect of ETFs, commplex ETFs, and structured bonds |
250 | 282 |
| Intangible assets | 1,795 | 1,760 | Others | 9,756 | 8,863 |
| Cash and other cash equivalents | 1,710 | 1,732 | 0 | 0 | |
| Others | 9,804 | 9,817 | Total equity | 7,128 | 6,636 |
| Total Assets | 111,638 | 110,064 | Total equity and liabilities | 111,638 | 110,064 |

| AM | Asset Management; i.e. Excellence Nessuah |
|---|---|
| AUM | Assets Under Management; the total market value of all the investments that are managed by the Group |
| Bps | Basis Points; 1 basis points is .01% |
| CGU | Cost Generating Unit |
| CI | Comprehensive Income |
| CLR | Combined Loss Ratio |
| CO | Corporate, Other and Consolidation |
| CPI | Consumer Price Index; measures the average change of prices in an agreed upon basket of consumer goods and services over time |
| CSM | Contractual Service Margin |
| D&O | Directors and Officers Liability Insurance |
| DAC | Deferred Acquisition Cost |
| ESOP | Employee Stock Ownership Plan; workplace benefit program, that provides the employees with ownership interest in the company. |
| ETF | Exchange Traded Fund; an open end, tradable basket of securities that tracks an underling index, sector, or security type |
| Fixed-Rate Gov Bonds | A government issued bond for which the interest income payment is agreed upon and does not change |
| FX | Foreign Exchange Currency |
| Gama | Financial services and credit company owned by the Phoenix Group |
| Illiquidity Premium | or Liquidity Premium; premium demanded by investors when any given security cannot be easily converted into cash for its fair market value. |
| IMF | International Monetary Fund |
| Index Linked Gov Bonds | A government issued bond for which the interest income payment is related (or linked) to the CPI |
| LAT | Liability Adequacy Test |
| Liquidity Premium | See Illiquidity Premium |
| LOB | Line of Business |
| LTC | Long Term Care insurance; typically helps pay for costs associated with long term care |
| LTS | Long Term Services; including but not limited to Life, Provident and Pension funds |
| Marketable Securities | Liquid financial assets that can be quickly converted into cash; most are trading assets |
| MF | Management Fees; wages charged by a financial manager | ||
|---|---|---|---|
| Moody's | A credit risk rating agency | ||
| MSCI | Morgan Stanley Capital International Emerging Markets Index; measures the performance in equity markets, specifically in global emerging markets |
||
| Mutual Fund | Open end, non-tradable basket of securities that tracks the performance of an undelaying index, sector, or security type | ||
| Net Inflows | The net amount of new cash, excluding the impact of investment market value; calculated by subtracting withdrawals from new deposits |
||
| NIS | New Israeli Shekel | ||
| Non-Marketable Securities | Asset group that is considered to be difficult to buy or sell due to the fact they are not traded on any major exchange; could include government issued debt securities, limited partnerships, real estate investments and more |
||
| Nostro | The account in which a financial institution manages its own funds | ||
| OPEX | Operational Expenses | ||
| P&C | Property and Casualty insurance | ||
| PH | Phoenix holdings | ||
| PHI | Permanent Health Insurance | ||
| PI | Phoenix insurance | ||
| PLI | Professional Liability insurance | ||
| Reinsurance | A balancing risk strategy; one or more insurers that share the liability | ||
| Revenue | All encompassing streams of income; including, but not limited to: premium, management fees, benefit contributions | ||
| ROE | Return On Equity; calculated by dividing net income over total equity | ||
| SME60 | "the Rest Index"; tracks the performance of the 60 largest market value companies that are excluded from the Tel Aviv Stock Exchange |
||
| Tel Bond 20 | Index that tracks the performance of the 20 largest Index Linked Corporate Bonds in terms of market value | ||
| Tel Bond 40 | Index that tracks the performance of the 40 largest Index Linked Corporate Bonds in terms of market value | ||
| Tel Bond 60 | Index that tracks the performance of the 60 largest Index linked Corporate Bonds in terms of market value | ||
| TLV 125 | An index that tracks the performance of the 125 largest market value companies in the Tel-Aviv Stock Exchange | ||
| TLV 35 | An index that tracks the performance of the 35 largest market value companies in the TLV Stock Exchange | ||
| TLV 90 | An index that tracks the performance of the 90 largest market value companies in the TLV stock Exchange | ||
| Workers' Compensation Insurance | Insurance coverage for employees' injuries or sickness | ||
| Yield Curve | A line that plots interest rates of bonds with equal credit risk with different maturity dates in the future | ||
Q3 2020 This presentation may include information that is presented differently from the way it was presented in the company's official reports, some information may be presented and/or categorized and/or edited and/or segmented differently from the company's official past reports. Moreover, this presentation includes information that may be present in the presentation but have not been included in the company official report, or have not been presented in the same way it is presented in this presentation, and is accurate to the company's knowledge, only as of the date they are presented.
Furthermore, the presentation includes data and assessments based on external sources, the contents of which were not independently tested by the Company and therefore the Company is not responsible for their accuracy. This presentation was prepared for the sake of convenience and brevity and is not a substitute for a review of the Company public reports, which contain complete information about the Company, before making any decision to invest in the Company's securities.
Some of the information in this presentation that does not refer to historical facts constitutes forward-looking information, as defined in the Securities Law 1968. Forwardlooking information reflects our the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties (such as Covid-19 impacts) that could cause actual results to differ materially from those contemplated. The Forward-looking information shall not be considered as a representation, warranty, declaration, obligation, undertaking and/or commitment, of any kind, made or owed by the Company and/or its directors, officers, employees, representatives. You should not unduly rely on any forward-looking information. The forward-looking information speaks only as of the date of this presentation, and the Company assume no obligation to update or revise the forward-looking information for any reason.
Financial Statements Investors Presentation

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.